biomed devic servic
updat mix bag dtc test take
step back reiter buy lower pt
deliv beat top bottom line rais bottom line
guid rais ep guid due announc deconsolid
dtc compani helix undergo transform new ceo chang new
strateg shift see page guid street expect revenu
even load though
compani indic expect revenu hail global pop seq
lower array revenue guid flat lsd off-set higher
growth sequenc view mix reiter buy rate sinc less
human ever sequenc clinic sequenc grow
rapidli extrem low base narrowli trim revenu estim lower
pt
posit realiz order first time ever
first time size novaseq pull-through
think expect ramp higher process record
number dtc sampl deconsolid helix remov
typic dilut indic clinic revenu grew
consum shipment continu move clinic
outpac research consum growth reiter guid
y/i growth consum help expect rev pop
neg guid rev y/i
street back-end load revenu
necessit strong ramp achiev growth consum year
dtc array achiev record number sampl volum
clarifi revenu miss expect believ
ancestri miss helix gener revenu result
lower array growth guid flat lsd growth
read-through lower outlook dtc shift strategi helix neg
read-through orasur nasdaq buy lesser extent labcorp
result revenu y/ beat
driven y/i growth servic driven higher revenu
oncolog collabor record number dtc array volum coupl
growth seq consum match estim seq instrument
declin y/i expect indic novaseq order
slightli exceed expect shipment slip time
servic revenu y/i beat
forecast y/i adj ep beat adj gm
beat adj om beat forecast ex-helix now-pro
forma om would
price close busi april
domin global leader next
gener sequenc instrument
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
guide/model reiter revenue guid tweak
compon lower array lower services/oth helix higher sequenc
rais adj ep guid y/i account
helix deconsolid vs our/street trim revenu growth
estim rais adj ep estim
trim revenu forecast rais
adj ep estim higher adj ep estim
predominantli result compani beat posit benefit
lower pt lower price target use
multipl adj ep estim
use lower multipl given lower visibl pro-forma dtc array revenu
growth addit back-end load revenu year
helix news custom helix announc former execut
marc stapley hire becom chairman ceo helix replac outgo
ceo robin thurston simultan announc deconsolid
helix thu longer equiti stake helix represent
helix board helix continu use sequenc offer exom assay
though unclear us integr app store go forward furthermor
helix announc modifi strateg busi focu expand
includ multipl health system payer research interest sequenc larg
popul view shift part driven helix success work renown
ihi healthi nevada project sequenc nevadan record
time expand nevadan like disappoint
uptak to-dat app-stor applic said believ helix
ever launch killer-app perhap compel health-ori app could fill
need helix announc launch orlando-florida pop seq project
initi aim peopl believ upsiz later togeth
adventhealth name wholem studi idea studi enabl
floridian better understand genom learn genom play role
integr health system help prevent diagnos treat diseas
project provid volunt result famili hypercholesterolemia screen
genet ancestri well trait provid helix
pacbio updat indic continu expect acquisit pacbio
complet accord press releas earn call
compani indic plan complet deal summer may pars
week june juli compani statement close deal
summer semant appear mark slight shift recal earli nov
announc acquisit long-read sequenc leader pacbio
ev street rev largest announc acquisit year
bought solexa deal ad sharehold valu
pacbio deal remain subject regulatori clearanc believ may pose
challeng given estim togeth produc
world genom inform uncertainti regulatori clearanc appear
reflect trade spread trade today vs
sh offer price manag confid help fill need
marketplac long-read market acknowledg complementari ilmn
domin short-read sequenc synthesi sb
dtc mysteri iilmn report record number dtc array sampl
grew y/i indic revenu lower expect
time provid guidanc earlier januari result lower
guid array expect array revenu roughli flat y/i
prior outlook low-singl digit compani take even cautiou view
dtc test cautiou view stem close dialogu compani
larg custom ancestri still provid clear reason
stress market shift ancestri genealog
toward health said given news helix undergo strateg shift
toward pop seq possibl de-emphasize applic app store
entir possibl demand dtc test ancestri genealog trait
either declin could reach certain level matur clear us
buy unchang target price april
biomed devic servic
and/or ancestri could migrat array exom plu either
provid may take pedal metal kit discount tv advertis
bottom line liter know go convict
acceler diminish congruent lower guid
year bigger uncertainti dtc demand beyond
lower number dtc test know correct pro-forma
growth rate remain puzzl remind nearli direct-to-
consum test order alon use array technolog
perform year ago bit concern
would tough comp clearli mark banner year dtc
test growth rate appear flatten
exom patient talk larg health systems/idn
exom sequenc patient clinic set indic
partnership geising spur convers larg system
integr deliveri network believ greater adopt systemat would
add major upsid sequenc consum growth think take
time play
buy unchang target price april
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price april
biomed devic servic
buy unchang target price april
biomed devic servic
buy unchang target price april
biomed devic servic
buy unchang target price april
biomed devic servic
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin april et
date time product april et
pt use multipl adj ep estim
laboratori corpor america hold lh
price target lh appli multipl adj ep
price target base use multipl revenu estim discount back two year
discount rate addit ad compani net cash posit approxim
risk achiev target price valuat
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
buy unchang target price april
biomed devic servic
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
